lergotrile

02/01/1979 - "Lergotrile in Parkinson disease: further studies."
09/04/1976 - "Lergotrile in Parkinson's disease."
05/01/1975 - "In 13 patients with Parkinson's disease treated with lergotrile (up to 12 mg a day), overall improvement was observed in five. "
03/01/1978 - "Lergotrile has also been found to be a potent dopaminergic agonist and thus to be effective in Parkinson's disease. "
10/01/1978 - "Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease."

07/01/1984 - "Although withdrawn from clinical trials because of liver toxicity, the ergot derivative lergotrile has been useful in the treatment of disorders involving dopaminergic systems (e.g., parkinsonism). "
07/01/1978 - "Lergotrile in the treatment of parkinsonism."
01/01/1980 - "1. When initially given to patients with idiopathic parkinsonism, lergotrile induced marked supine arterial hypotension. "
01/01/1977 - "Effects of lergotrile on schizophrenia & drug induced parkinsonism."
04/01/1978 - "The role for each drug in the treatment of parkinsonism is likely to be determined by factors such as cost (bromocriptine) and hepatotoxicity (lergotrile)."

05/01/1975 - "The administration of lergotrile resulted in a dose-dependent reduction in the intensity of tremor in the monkeys. "
05/01/1975 - "In a subgroup of four patients treated with a higher dose of lergotrile (up to 20 mg a day), further improvement in rigidity and bradykinesia was noted, but again, only improvement in tremor was statistically significant. "
01/01/1978 - "The antiparkinsonian activity of bromocriptine and of lergotrile was investigated in monkeys with surgically induced tremor and in parkinsonian patients. "
02/01/1979 - "Thirty-nine patients who could tolerate at least 20 mg per day lergotrile (thus considered "adequately treated") had significant descreases in rigidity, tremor, bradykinesia, gait disturbance, and total score without increased involuntary movements. "
11/28/1977 - "Among 20 patients completing a six-month trial, there was a significant (P less than .01) reduction in rigidity, tremor, bradykinesia, gait disturbance, and total score when lergotrile was added to levodopa plus carbidopa. "

05/01/1975 - "In a subgroup of four patients treated with a higher dose of lergotrile (up to 20 mg a day), further improvement in rigidity and bradykinesia was noted, but again, only improvement in tremor was statistically significant. "
02/01/1979 - "Thirty-nine patients who could tolerate at least 20 mg per day lergotrile (thus considered "adequately treated") had significant descreases in rigidity, tremor, bradykinesia, gait disturbance, and total score without increased involuntary movements. "
11/28/1977 - "Among 20 patients completing a six-month trial, there was a significant (P less than .01) reduction in rigidity, tremor, bradykinesia, gait disturbance, and total score when lergotrile was added to levodopa plus carbidopa. "
07/01/1979 - "Both groups had significantly decreased rigidity, tremor, bradykinesia and gait disturbance upon addition of bromocriptine or lergotrile to levodopa. "

10/01/1976 - "Tumors that were growing or static in lergotrile-treated animals showed reduced capacity to bind labeled estradiol. "
04/01/1977 - "On the other hand, estradiol did not stimulate tumor growth when serum prolactin was depressed to undetectable levels by lergotrile. "
11/01/1977 - "Those ergot compounds and ergolines that proved to be highly effective in reducing tumor size or in inducing regression of tumors to nonpalpability were Deprenon (D-6-methyl-8-ergolin-I-ylacetic acid amide) and ergocryptine; effective to an intermediate degree were Dironyl [N-(D-6-methyl-8-isoergolin-I-yl)-N',N'-diethylurea], ergocornine, and Lysenyl [N-(D-6-methyl-8-isoergolenyl)-N',N'-diethyl-urea]; and effective to a minimal degree were Lergotrile (2-chloro-6-methylergoline-8beta-acetonitrile), CB-154, and 6605-VUFB (D-6-methyl-8-cyanomethylergolin-I). "
03/01/1977 - " Gonadotropin-releasing hormones can be administered in several ways, provoke different reactions in different women, and are subject to several contraindications; 2) transphenoidal surgery for hypersecretory hypophysary tumors, or microsurgery of the hypophysis, which allows the identification of tumors smaller than 10mm, and which is used in the treatment of galactorrhea; 3) the use of ergot alkaloids derivates, such as bromocriptine or Lergotrile, to provoke menstruation and ovulation; 4) the clinical use of danazol in the treatment of endometriosis and in induction of ovulation; and 5) the treatment of primary dysmenorrhea by the use of synthetic inhibitors or by the use of prostaglandins."